Orbital Fat Loss and Lash Serums: What Prostaglandin Users Should Know

Part of Series on Lash Serum Safety

Last updated: May 9, 2026.

Periorbital fat atrophy, formally called prostaglandin-associated periorbitopathy (PAP), is a documented adverse effect of topical prostaglandin analog medications and certain over-the-counter cosmetic lash serums. The condition produces a hollow or sunken appearance around the eyes due to a reduction in the volume of orbital fat pads. This page reviews the current peer-reviewed evidence: which ingredients are associated with the effect, the underlying mechanism, incidence, reversibility, regulatory positions, and clinical guidance for affected individuals.

Key Facts

• Periorbital fat atrophy is a documented adverse effect of topical prostaglandin analogs, including bimatoprost (Latisse, Lumigan), latanoprost (Xalatan), travoprost (Travatan), tafluprost (Zioptan), and the over-the-counter cosmetic ingredient isopropyl cloprostenate.
• The condition is formally named prostaglandin-associated periorbitopathy (PAP), or prostaglandin-associated periorbitopathy syndrome (PAPS), and produces a visible hollow or sunken appearance around the eyes due to shrinkage of orbital fat pads.
• The FDA-approved prescribing information for Latisse (bimatoprost 0.03%) lists, under postmarketing experience, periorbital and lid changes associated with periorbital fat atrophy.
• The European Union's Scientific Committee on Consumer Safety adopted Opinion SCCS/1680/25 on 2 February 2026 (published 10 February 2026), concluding that isopropyl cloprostenate, Ethyl Tafluprostamide (DDDE), and methylamido-dihydro-noralfaprostal (MDN) cannot be considered safe for use in cosmetic products.
• Periorbital fat atrophy from prostaglandin analogs is partially to fully reversible after discontinuation in most documented cases. At least one case of persistent change has been reported. Surgical correction is available for cases that do not resolve.

Quick Reference: Prostaglandin Analogs in Lash Products

The following compounds account for most prostaglandin analog exposure from lash and brow products. Regulatory status reflects the published positions of the named authorities as of this page's last update. Product formulations change over time; consult current product labels for verification.

Ingredient (INCI)	Commonly Associated Products	Regulatory Status
Bimatoprost	Associated with products including Latisse and Lumigan	Prescription drug; FDA-approved as Latisse for eyelash hypotrichosis; not a permitted cosmetic ingredient in the United States
Isopropyl cloprostenate (IPCP)	Associated with numerous over-the-counter lash and brow serums	Marketed as an OTC cosmetic ingredient; judged not safe for cosmetic use by the EU SCCS (Opinion SCCS/1680/25, 2026)
Ethyl Tafluprostamide (DDDE)	Associated with over-the-counter lash and brow serums	Marketed as an OTC cosmetic ingredient; judged not safe for cosmetic use by the EU SCCS (2026)
Methylamido-dihydro-noralfaprostal (MDN)	Associated with over-the-counter lash and brow serums	Marketed as an OTC cosmetic ingredient; judged not safe for cosmetic use by the EU SCCS (2026)

What Ingredients Are Considered Prostaglandin Analogs?

Many consumers do not realize that several common lash serum and ophthalmic ingredients are members of the prostaglandin analog class. Chemical names in this class typically contain the fragments -prost- or -cloprostenol-.

Ingredient	Common product names	Regulatory status	Class
Bimatoprost	Latisse, Lumigan	Prescription	Prostaglandin F2α analog
Latanoprost	Xalatan	Prescription	Prostaglandin F2α analog
Travoprost	Travatan, Travatan Z	Prescription	Prostaglandin F2α analog
Tafluprost	Zioptan	Prescription	Prostaglandin F2α analog
Isopropyl unoprostone	Rescula (in some markets)	Prescription	Prostaglandin analog
Isopropyl cloprostenate (IPCP, also called Cloprostenol Isopropyl Ester)	Numerous OTC lash serums	OTC cosmetic	Prostaglandin analog
Ethyl Tafluprostamide (DDDE)	OTC lash serums	OTC cosmetic	Prostaglandin analog
Methylamido-dihydro-noralfaprostal (MDN)	OTC lash serums	OTC cosmetic	Prostaglandin analog

All compounds in this class share the same general pharmacological mechanism: agonism of the prostanoid FP receptor. The FP receptor is expressed in tissues including orbital adipose tissue, and its activation has been associated with the periorbital changes described in this document.

What Orbital Fat Loss Looks Like

The most characteristic sign is a deepening of the upper eyelid sulcus, the crease between the upper lid and the brow, creating a sunken or hollow appearance around the eyes. The full clinical picture, formally called prostaglandin-associated periorbitopathy, can include:

• Deepening of the upper eyelid sulcus (DUES)
• Periorbital fat atrophy (loss of fat pad fullness above and below the eye)
• Mild enophthalmos (the eyeball appears set further back in the socket)
• Loss of lower eyelid fullness and flattening of lower eyelid bags
• Involution of dermatochalasis (the natural loose skin fold of the upper lid appears to shrink)
• Upper eyelid ptosis (drooping)
• Inferior scleral show (more white of the eye visible below the iris)
• Tight, prominent eyelid vessels

Earlier names for the condition appearing in the literature include deep superior sulcus syndrome (DSSS), deepening of the upper eyelid sulcus (DUES), and prostaglandin-associated orbitopathy. The unified term PAP was proposed by Pasquale and Berke. The American Academy of Ophthalmology's clinician encyclopedia (EyeWiki) recognizes PAP as a documented side effect of prostaglandin analog topical therapy.

The fat pads most affected are the pre-aponeurotic orbital fat (the compartment immediately accessible to topically absorbed drug) and the extraconal orbital fat. Histological analysis of treated eyes shows increased adipocyte density (more cells per area, each individually smaller), consistent with cellular atrophy rather than cell death. Bimatoprost-treated eyes show the most pronounced changes on biopsy, followed by travoprost and latanoprost.

The condition was first described in the peer-reviewed literature in 2004 by Peplinski and Smith, who reported three patients on unilateral bimatoprost therapy who developed ipsilateral lid sulcus deepening. A confirming case series was published by Filippopoulos et al. in 2008. Since these initial reports, the condition has been described with all commercially available topical prostaglandin analogs.

↑ Back to top

Why Prostaglandin Analogs Can Cause It

The accepted mechanism centers on agonism of the prostanoid FP receptor on orbital preadipocytes and adipocytes. Prostaglandin F2-alpha and its analogs bind the FP receptor, activating the mitogen-activated protein kinase (MAPK) signaling cascade. This phosphorylates and inactivates peroxisome proliferator-activated receptor gamma (PPARγ), the master regulator of adipocyte differentiation. With PPARγ inactivated, preadipocytes cannot mature into lipid-storing fat cells, and fat accumulation is suppressed.

In vitro studies confirm this mechanism. Choi et al. (2014) treated human orbital adipose precursors with PGF2α and the four major prostaglandin analogs and measured PPAR-gamma and lipoprotein lipase expression by RT-PCR. All compounds significantly downregulated PPARγ and inhibited lipid accumulation. Bimatoprost produced the greatest downregulation. Taketani et al. (2014) confirmed that all four major prostaglandin analogs significantly inhibited adipogenesis at concentrations of 10 nM and 100 nM via FP receptor stimulation. Kim et al. (2014) showed both latanoprost and travoprost inhibited late-stage preadipocyte differentiation by significantly decreasing G3PDH activity, with travoprost producing a more pronounced effect.

A complementary mechanism involves FP receptor-mediated downregulation of fatty acid binding protein (FABP), a protein essential for lipid uptake in existing adipocytes. This suggests prostaglandin analogs not only prevent new fat cell formation but may also reduce lipid storage in existing cells. Antunes et al. (2013) confirmed that FP receptor stimulation also promotes lipolysis (breakdown of stored lipid) in mature orbital adipocytes.

A pharmacokinetic study in cynomolgus monkeys found that periorbital tissue absorbs far more drug than the eye itself: eyelid specimens contained more than 2,000 times the bimatoprost concentration found in the aqueous humor after a single topical dose. This high periorbital exposure is consistent with PAP being a clinically prominent effect even with cosmetically applied preparations.

In vivo histological analysis (Park et al.) found significantly increased mean adipocyte density in eyelid specimens from bimatoprost-treated eyes, along with clumped adipocyte nuclei consistent with atrophy. No significant inflammatory infiltrate was identified, indicating that inflammation is not the primary driver.

↑ Back to top

Ingredients Associated with the Effect

Bimatoprost (Latisse, Lumigan)

• Regulatory status: Prescription-only.
• Uses: FDA-approved as Lumigan (0.03%, 0.01%) for glaucoma and ocular hypertension. FDA-approved as Latisse (0.03%) for cosmetic eyelash hypotrichosis.
• Evidence: Most consistently documented in the literature. PAP frequency reported at 93.3% in one cross-sectional study (Kucukevcilioglu et al., 2014), with upper lid sulcus deepening documented in 80% of bimatoprost-treated eyes. Bimatoprost produces the most pronounced reduction in orbital adipocyte size on biopsy. The FDA postmarketing labeling for Latisse explicitly lists periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus and eyelid ptosis.

Latanoprost (Xalatan)

• Regulatory status: Prescription-only.
• Uses: Glaucoma and ocular hypertension treatment.
• Evidence: PAP reported at lower frequency and severity than bimatoprost. PAP frequency 41.4%, DUES 15.7% (versus 93.3% and 80% with bimatoprost) in one comparative study. In vitro, latanoprost has the weakest antiadipogenic effect among the four main prostaglandin analogs. Switching from bimatoprost to latanoprost has been associated with reduction or resolution of DUES in a majority of patients (Sakata et al.).

Travoprost (Travatan)

• Regulatory status: Prescription-only.
• Uses: Glaucoma and ocular hypertension treatment.
• Evidence: PAP frequency reported at 70%, DUES at 45% in one comparative study. Antiadipogenic effect intermediate between bimatoprost and latanoprost.

Tafluprost (Zioptan)

• Regulatory status: Prescription-only.
• Uses: Glaucoma and ocular hypertension treatment. Preservative-free formulation available.
• Evidence: DUES reported in 19% of patients within 90 days of initiation (Maruyama et al.). Tafluprost acid significantly inhibits adipogenesis at 10 nM and 100 nM via FP receptor stimulation.

Isopropyl Cloprostenate

• Regulatory status: Over-the-counter cosmetic ingredient. Not FDA-approved as a drug. Marketed as a hair-conditioning agent under INCI classification.
• Uses: Eyelash and eyebrow growth serums sold without prescription.
• Evidence: A case report in Aesthetic Surgery Journal (2022) described a 35-year-old woman who developed thin, wrinkled, darker skin and periorbital hollowing after 10 months of treatment with an isopropyl cloprostenate-containing lash serum, with effects reversing approximately 6 months after discontinuation. A 2024 review in Journal of Cosmetic Dermatology documented similar periocular changes. In December 2025, France's national health agency ANSES published a cosmetovigilance alert in VigilAnses bulletin Issue 27 attributing iris darkening and periorbital fat loss to isopropyl cloprostenate. The European Union's SCCS adopted Opinion SCCS/1680/25 on 2 February 2026 (published 10 February 2026) concluding that isopropyl cloprostenate cannot be considered safe for cosmetic use.

Ethyl Tafluprostamide (DDDE)

• Regulatory status: OTC cosmetic ingredient. "Ethyl Tafluprostamide" is the official EU INCI/SCCS designation; "DDDE" (Dechloro Dihydroxy Difluoro Ethylcloprostenolamide) is the common alternate name in the cosmetic literature.
• Uses: Lash and brow growth serums.
• Evidence: Assessed by the SCCS in their 2025 to 2026 evaluation. Concluded not safe for cosmetic use. The SCCS noted DDDE has pharmacological activity consistent with FP receptor agonism at proposed cosmetic concentrations.

Methylamido-Dihydro-Noralfaprostal (MDN)

• Regulatory status: OTC cosmetic ingredient.
• Uses: Lash and brow growth serums.
• Evidence: Assessed by the SCCS in SCCS/1680/25 (adopted February 2026). Concluded not safe for cosmetic use at the proposed 0.03% maximum concentration.

Isopropyl Unoprostone

• Regulatory status: Prescription ophthalmic drug in some countries.
• Evidence: DUES has been reported with isopropyl unoprostone use.

A Note on Reading Ingredient Lists

In lash serums and ophthalmic drops, prostaglandin-class compounds typically contain the chemical fragments -prost- or -cloprostenol- in their name. Any ingredient containing these fragments is, or is closely related to, a prostaglandin analog.

↑ Back to top

Incidence

The available evidence on PAP incidence comes primarily from observational studies (cross-sectional and prospective cohort designs) of glaucoma patients on prescription prostaglandin analogs. Randomized controlled trials specifically targeting periorbital fat atrophy as a primary endpoint have not been published. Cosmetic-use incidence is even more limited and depends on individual case reports and regulatory cosmetovigilance signals (see Areas of Uncertainty below).

A cross-sectional study of 343 subjects (Shah et al., 2013) found that current prostaglandin analog users had roughly 2.3× the odds of involution of dermatochalasis (OR 2.30; 95% CI 1.43–3.69) and 2.5× the odds of lower-lid steatoblepharon loss (OR 2.49; 95% CI 1.54–4.03) compared with non-users.

A comparative cross-sectional study by Kucukevcilioglu et al. (2014) in Clinical and Experimental Ophthalmology reported the following frequencies of PAP across three prostaglandin analogs:

• Bimatoprost group: PAP in 93.3% of patients. DUES in 80%.
• Travoprost group: PAP in 70%. DUES in 45%.
• Latanoprost group: PAP in 41.4%. DUES in 15.7%.

A 2011 prospective observational study (Aihara et al.) found 44% of patients developed DUES within 1 month of switching from latanoprost to bimatoprost, rising to 60% by 6 months. A prospective cohort study of tafluprost (Maruyama et al.) found 19% developed DUES within 90 days of initiation, and only 17% of those affected had perceived a difference themselves.

A 2022 review in Seminars in Ophthalmology estimated periocular change in more than 40% of patients treated with prostaglandin analogs, with patients over 60 years showing greater risk of clinical presentation.

The true incidence in OTC cosmetic lash serums is unknown. Cosmetic products containing isopropyl cloprostenate, DDDE, or MDN are not subject to mandatory adverse event reporting equivalent to that for prescription drugs. The SCCS noted this lack of post-market safety data as a specific concern in its 2025 to 2026 opinion.

Risk factors identified in multivariate analysis (Park et al., 2017) include older age, bimatoprost use, and travoprost use, with higher BMI identified as a protective factor. Older patients consistently show greater susceptibility, likely because age-related baseline orbital fat depletion makes prostaglandin-induced changes more clinically apparent.

↑ Back to top

Is It Reversible?

Published evidence supports partial reversibility after discontinuation of prostaglandin analog therapy in most documented cases. Complete reversal occurs in some cases. Partial reversal (improvement without full return to baseline) is most commonly documented. At least one case of persistent change has been reported.

Evidence supporting reversal

• Peplinski and Smith (2004): Original case series describing reversal of DUES after bimatoprost discontinuation.
• Filippopoulos et al. (2008): Partial reversibility across a five-patient series.
• Abalo-Lojo et al. (2023): Prospective evaluation of nine patients who discontinued PGA therapy, followed for one year. All nine patients showed improvement, including DUES improvement in 8 of 9 and partial recovery of lower eyelid fat pad loss in 4 eyes.
• Sakata et al.: 85% of affected Japanese patients had DUES improvement within 2 months of switching back from bimatoprost to latanoprost.
• Pasquale (2011): Clinical observation of PAP effects subsiding in 1 to 3 months after PGA discontinuation.
• Aesthetic Surgery Journal (2022): Case of periorbital hollowing from a cosmetic lash serum that recovered approximately 6 months after discontinuation, with self-reported 90 to 95% improvement.

Evidence of persistent or incomplete reversal

• Aydin et al. (2010): Documented at least one case with incomplete resolution and the first report of potentially irreversible DUES.

Typical timeline

• Earliest improvement documented: 4 to 6 weeks after discontinuation
• Most reversal cases show improvement within 1 to 12 months
• Full resolution (when it occurs) typically observed within 3 to 24 months
• At one year post-discontinuation, improvement is present in the majority of reported cases, though completeness varies

Surgical and procedural correction

For persistent cases causing functional or cosmetic concerns, the literature describes:

• Autologous fat grafting to restore orbital volume
• Calcium hydroxyapatite (CaHA) filler injection for mild to moderate volume restoration
• Combined CaHA and autologous fat grafting for severe cases

A 2025 paper in Clinical Ophthalmology (Di Maria et al.) proposed a classification and therapeutic algorithm stratifying treatment by severity. Surgical decisions require evaluation by a qualified oculoplastic surgeon.

What the literature does not establish

There is no reliable predictor of who will experience complete versus partial versus no reversal. There are no controlled trials comparing reversal rates between agents or durations of exposure. No head-to-head comparison of surgical correction methods has been published as of early 2026.

↑ Back to top

What the FDA Says

What Health Canada Says

What the European SCCS Concluded in 2026

Other Regulatory and Professional Body Recognition

ANSES (France). France's national health agency published a cosmetovigilance alert in its VigilAnses bulletin Issue 27 (December 2025) attributing iris darkening and periorbital fat loss to isopropyl cloprostenate following an adverse reaction case received in February 2025 involving five months of daily use of a cosmetic lash serum. The full bulletin is available at vigilanses.anses.fr.

American Academy of Ophthalmology. The AAO's clinician encyclopedia EyeWiki maintains a dedicated entry on prostaglandin-associated periorbitopathy recognizing it as a side effect of prostaglandin analogue topical therapy. PAP is referenced in AAO Preferred Practice Pattern content on glaucoma management.

ASOPRS. The American Society of Ophthalmic Plastic and Reconstructive Surgery has addressed PAP through peer-reviewed publications by member surgeons and specialty education. ASOPRS members are the primary specialists who diagnose and surgically manage persistent PAP.

↑ Back to top

When to Speak with an Ophthalmologist

Anyone using a prostaglandin-containing product, prescription or cosmetic, who notices any of the following should consult a physician:

• New or progressive hollowing or sunken appearance around the eyes
• Visible asymmetry between the two eyes (most apparent with unilateral use)
• A sudden change in the appearance of the upper eyelid crease or sulcus
• New drooping of the upper eyelid
• Increase in visible white of the eye below the iris
• Iris color darkening
• Skin darkening around the eyes

Recommended steps

1. Discontinue the product if medically safe to do so. If the product is a prescription glaucoma medication, do not stop without consulting the prescribing ophthalmologist, as alternatives to prostaglandin analogs exist for intraocular pressure management.
2. Document the change with photographs, ideally compared to images from before product use.
3. See an ophthalmologist for evaluation. They can assess for both PAP-related changes and unrelated conditions that may produce similar appearances (age-related changes, thyroid eye disease, weight loss, prior surgery, orbital pathology).
4. Consider an oculoplastic surgeon referral if changes are severe, persistent beyond 6 to 12 months after discontinuation, or require surgical correction.

Differential diagnosis the clinician will rule out: age-related involutional changes, weight loss, thyroid eye disease, orbital fracture or bony remodeling, scirrhous orbital metastasis, hemifacial atrophy, and post-surgical changes.

↑ Back to top

Areas of Uncertainty

Authoritative medical references identify what is not known alongside what is established. Several aspects of prostaglandin-associated periorbitopathy remain incompletely characterized in the published literature.

Relative mechanistic contributions

What the literature has not fully resolved: the relative contribution of inhibited preadipocyte differentiation versus accelerated atrophy of existing adipocytes in the in vivo effect. Why bimatoprost produces more pronounced changes than latanoprost at equivalent clinical doses is also not fully established.

Reversibility predictors are not established

Published evidence supports partial reversibility in most documented cases after discontinuation, with complete reversal in some cases and persistent change in at least one published case. There is no reliable predictor of who will experience complete versus partial versus no reversal. Controlled comparisons of reversal rates between different prostaglandin analogs have not been published.

Cosmetic-use incidence is unknown

Unlike prescription drugs, cosmetic products containing isopropyl cloprostenate, DDDE, or MDN are not subject to mandatory adverse event reporting equivalent to that for drugs. Existing evidence in the cosmetic context is limited to individual case reports and regulatory cosmetovigilance signals (the ANSES alert and SCCS opinion cited above). Systematic incidence data from large cosmetic-use cohorts do not exist.

Long-term low-dose exposure outcomes

Outcomes from sustained low-dose cosmetic exposure across years rather than months have not been systematically studied. Most published cases describe months-to-low-years of use; multi-year cosmetic exposure trajectories are poorly characterized.

Genetic susceptibility factors

Whether individual genetic variants in FP receptor expression or adipocyte biology predispose particular individuals to PAP has not been studied. No genetic screening test exists to identify higher-risk individuals before initiating treatment.

Concentration-response at cosmetic-use doses

In vitro dose-response data are available at 10 nM and 100 nM concentrations, with both showing significant adipogenesis inhibition. The minimum in vivo exposure required to produce clinically detectable periorbital change has not been established for cosmetic-use concentrations. The SCCS noted in 2026 that no concentration could be advised as safe for cosmetic use of isopropyl cloprostenate, DDDE, or MDN.

Newer-generation prostaglandin analogs

Modified prostaglandin compounds (such as DDDE and MDN) have been marketed as having improved safety profiles relative to earlier prostaglandin analogs. Long-term safety data on these compounds is emerging. The SCCS opinion of February 2026 concluded these compounds also cannot be considered safe for cosmetic use at proposed concentrations.

Causation versus association

Most published evidence on PAP is observational or mechanistic rather than derived from randomized controlled trials. The literature supports a strong documented association between prostaglandin analog exposure and periorbital changes, supported by a biologically plausible and well-characterized mechanism. Causal proof through controlled trial design specifically for periorbital fat atrophy as a primary endpoint is incomplete.

↑ Back to top

Prostaglandin-Free Alternatives

Lash growth serums that do not contain prostaglandin analog ingredients work through different biological pathways and do not share the FP-receptor mechanism associated with periorbital fat atrophy. The most established alternative category is peptide-based lash serums, which use keratin-signaling peptides such as myristoyl pentapeptide-17 and follicle-conditioning compounds.

Trade-offs documented in the literature:

• Onset is slower. Peptide-based serums typically require 8 to 12 weeks of consistent use for visible results, compared with 4 to 6 weeks for prostaglandin analogs.
• Mechanism is different. Peptide-based growth depends on follicle support and lash conditioning rather than receptor agonism. Periorbital fat atrophy has not been reported in association with peptide-only formulations.
• Ingredient lists matter. Some products marketed as natural or peptide-based also contain prostaglandin analog co-ingredients. Any chemical name containing -prost- or -cloprostenol- identifies a prostaglandin analog.

Consumers seeking prostaglandin-free alternatives may prefer formulations that do not contain prostaglandin analog ingredients, hormone ingredients, or related compounds.

Plume Elite is formulated without prostaglandin analogs, hormone ingredients, isopropyl cloprostenate, DDDE, or MDN. The full ingredient list is available on the product page.

Frequently Asked Questions

Does Latisse cause orbital fat loss?

Yes. Latisse (bimatoprost 0.03%) lists periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus and eyelid ptosis in its FDA-approved postmarketing adverse events section. Bimatoprost is the prostaglandin analog most consistently associated with periorbital fat atrophy across published case series and comparative studies. One study reported PAP changes in 93.3% of bimatoprost users examined.

Can a single tube of lash serum cause orbital fat loss?

Published literature does not document periorbital fat atrophy from a single short-duration exposure. The earliest reported onset is approximately one month after starting prostaglandin analog therapy, and most cases involve weeks to months of continuous use. A case report involving a cosmetic lash serum documented periorbital hollowing after 10 months of daily use. Risk appears to increase with duration.

What is the difference between orbital fat loss and a "tired eye" appearance from aging?

Both can produce orbital hollowing, lid sulcus deepening, and a tired appearance. The key distinguishing factor is the temporal relationship to drug use. Prostaglandin-induced changes occur ipsilateral to drug exposure and, when one eye is treated, produce visible asymmetry between the two eyes that is not explained by normal aging. In bilateral drug use, distinguishing PAP from aging requires baseline photographs or comparison with pre-treatment images.

Are peptide-based lash serums associated with the same effect?

Peptide-based lash serums that do not contain prostaglandin analog ingredients (isopropyl cloprostenate, DDDE, MDN, bimatoprost, latanoprost, travoprost, tafluprost, or similar compounds) do not share the FP receptor mechanism that drives periorbital fat atrophy. Periorbital fat atrophy has not been reported in association with peptide-only lash formulations. Some products marketed with peptides also contain prostaglandin analog co-ingredients, so the full ingredient list should be confirmed.

What ingredients are considered prostaglandin analogs?

Prostaglandin analogs in lash serums and ophthalmic medications include bimatoprost (Latisse, Lumigan), latanoprost (Xalatan), travoprost (Travatan), tafluprost (Zioptan), isopropyl cloprostenate, DDDE, methylamido-dihydro-noralfaprostal (MDN), and isopropyl unoprostone. Chemical names typically contain the fragments -prost- or -cloprostenol-.

How long does it take for periorbital fat atrophy to develop?

Reported timelines range widely. Changes have been detected as early as 1 month and as late as approximately 5 years after initiation of prostaglandin analog therapy. A prospective study found 44% of patients developed DUES within 1 month of switching to bimatoprost, rising to 60% by 6 months. A case of periorbital hollowing from a cosmetic lash serum containing isopropyl cloprostenate developed over 10 months of daily use.

Is the effect dose-dependent?

Evidence suggests a dose-related effect: more potent prostaglandin analogs (bimatoprost) produce higher rates of PAP than less potent ones (latanoprost) at clinical doses. In vitro studies confirmed dose-dependent inhibition of adipogenesis at 10 nM and 100 nM concentrations. Whether reducing the concentration of a given PGA proportionally reduces the risk of periorbital fat atrophy has not been established in controlled clinical trials for cosmetic-use concentrations. The SCCS concluded it could not identify a safe concentration for isopropyl cloprostenate or DDDE in cosmetic products even at proposed low concentrations.

What should someone do if they think periorbital fat atrophy is happening to them?

Stop using the product if medically safe, and consult a physician. If the product is a prescription glaucoma medication, the prescribing ophthalmologist should be consulted before discontinuing, as alternatives to prostaglandin analogs exist for intraocular pressure management. Switching from bimatoprost to latanoprost has been associated with improvement of DUES in a majority of cases. If changes are cosmetically distressing or persistent, referral to an oculoplastic surgeon is appropriate.

Can children or teenagers be affected?

Yes. A 2020 study in Journal of Glaucoma by Yildiz et al. found that mild-to-moderate ocular adnexa changes can develop in children and young adults with long-term PGA exposure. The authors recommended that patients and families be educated about PAP when initiating monocular PGA therapy in pediatric patients.

Does this happen with all prostaglandin analogs equally?

No. Bimatoprost consistently produces the highest rate and severity of periorbital changes across comparative clinical studies, followed by travoprost. Latanoprost is associated with the lowest rates of PAP and the weakest antiadipogenic effect in vitro. One study reported PAP in 93.3% of bimatoprost users, 70% of travoprost users, and 41.4% of latanoprost users.

Are there any genetic or individual factors that increase risk?

Older age (particularly over 60 years) is the most consistently identified risk factor. Higher BMI has been identified as a potentially protective factor in one multivariate study. The type of PGA used and duration of exposure are additional variables. Genetic factors specifically predisposing individuals to PAP have not been characterized in the published literature as of early 2026. No genetic screening tests exist to identify high-risk patients before treatment.

Related Reading

• Latisse Side Effects: 7 Risks of Prostaglandin Lash Serums
• Prostaglandin-Free Lash Serums That Actually Work (2026)
• Does GrandeLASH Have Prostaglandin? Here's the Real Answer
• What is Isopropyl Cloprostenate?
• How to Grow Eyebrows: 8 Causes of Thinning and Real Fixes
• Cosmetic Colorants in Cosmetic Products: A Regulatory Overview

Sources

1. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optometry and Vision Science. 2004;81(8):574–577. PMID: 15300114.
2. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthalmic Plastic and Reconstructive Surgery. 2008;24(4):302–307. PMID: 18645437.
3. Choi YJ, et al. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Investigative Ophthalmology and Visual Science. 2014;55(3):1269–1276. PMID: 24508785.
4. Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clinical and Experimental Ophthalmology. 2014;42(2):126–131. PMID: 23844550.
5. Kim JW, et al. Topical prostaglandin analogue drugs inhibit adipocyte differentiation. Korean Journal of Ophthalmology. 2014;28(3):257–264. PMC: PMC4038732.
6. Antunes RA, et al. Effects of prostaglandin F2α on adipocyte biology relevant to prostaglandin-associated periorbitopathy. Investigative Ophthalmology and Visual Science. 2013;54(13):7856–7863. PMC: PMC3868384.
7. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Japanese Journal of Ophthalmology. 2011;55(1):22–27. PMID: 21222148.
8. Abalo-Lojo JM, et al. Improvement of prostaglandin-associated periorbitopathy after discontinuing treatment. Turkish Journal of Ophthalmology. 2023;53(1):8–12. PMC: PMC9973213.
9. Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Japanese Journal of Ophthalmology. 2011;55(6):600–604. PMID: 21953485.
10. Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013;8(5):e61638. PMC: PMC3664615.
11. Aydin S, Işikligil I, Tekşen YA, Kir E. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy. Cutaneous and Ocular Toxicology. 2010;29(3):212–216. PMID: 20394483.
12. Sakata R, Shirato S, Miyata K, Aihara M. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Japanese Journal of Ophthalmology. 2013;57(2):179–184. PMID: 23233196.
13. Maruyama K, Shirato S, Tsuchisaka A. Incidence of deepening of the upper eyelid sulcus after topical use of travoprost ophthalmic solution in Japanese. Journal of Glaucoma. 2014;23(3):160–163. PMC: PMC3716560.
14. Park KH, et al. Factors related to prostaglandin-associated periorbitopathy in patients treated with prostaglandin analogs. Journal of Glaucoma. 2017;26(5):e155–e159. PMID: 28379653.
15. Yildiz Balci S, et al. Prostaglandin-associated periorbitopathy in children and young adults. Journal of Glaucoma. 2020;29(12):e124–e127. PMID: 33008561.
16. Di Maria A, et al. Proposing a new classification for managing prostaglandin-induced enophthalmos (prostaglandin-associated periorbitopathy syndrome). Clinical Ophthalmology. 2025;19:1803–1814. PMC: PMC12276752.
17. Hall N, et al. Prostaglandin-associated periorbitopathy syndrome (PAPS). Seminars in Ophthalmology. 2022;37(3):344–350. PMID: 34852702.
18. Do Prostaglandin Analogue Lash Lengtheners Cause Eyelid Fat Atrophy? Aesthetic Surgery Journal. 2022. PMID: 35700523.
19. FDA Labeling, Latisse (bimatoprost ophthalmic solution 0.03%): NDA 022369/S-014, revised August 2021. accessdata.fda.gov
20. Health Canada, Latisse Product Monograph: AbbVie Corporation. LATISSE (bimatoprost) Product Monograph Including Patient Medication Information. Date of Revision: August 25, 2022. Submission Control Number 266211. abbvie.ca
21. European Commission, SCCS Opinion SCCS/1680/25: Scientific Committee on Consumer Safety, Opinion on prostaglandin analogues used in cosmetic products (Isopropyl Cloprostenate, MDN, Ethyl Tafluprostamide / DDDE). Adopted 2 February 2026; published 10 February 2026. health.ec.europa.eu
22. ANSES VigilAnses Bulletin Issue 27 (December 2025): Cosmetovigilance alert on eyelash growth serums containing isopropyl cloprostenate. vigilanses.anses.fr
23. EyeWiki, Prostaglandin Associated Periorbitopathy (American Academy of Ophthalmology). eyewiki.org

This page shares peer-reviewed literature, FDA product labeling, and official regulatory opinions current through May 2026. It is intended as educational reference content and is not a substitute for professional medical advice. If you are experiencing changes around your eyes while using a lash enhancement product, consult a qualified ophthalmologist or oculoplastic surgeon.